Walter H. Moos

Walter H. Moos

Auto-generated profile, based on publicly available information

Walter H. Moos

Department of Pharmaceutical Chemistry, School of Pharmacy, University of California San Francisco, San Francisco, CA, USA

Research Focus & Metrics

Academic Career Length

43Years (1984-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 1992 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
RZRonald N. Zuckermann
Ronald N. Zuckermann
JKJanice M. Kerr
Janice M. Kerr
SKStephen B. H. Kent
Stephen B. H. Kent
WMWalter H. Moos
Walter H. Moos

1 May 1995 in Drug Development Research
Verified
Journal Article
Closed access
PDF file
SMSusan M. Miller
Susan M. Miller
RSReyna J. Simon
Reyna J. Simon
SNSimon Ng
Simon Ng
RZRonald N. Zuckermann
Ronald N. Zuckermann
JKJanice M. Kerr
Janice M. Kerr
WMWalter H. Moos
Walter H. Moos

1 November 1994 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
SMSusan M. Miller
Susan M. Miller
RSReyna J. Simon
Reyna J. Simon
SNSimon Ng
Simon Ng
RZRonald N. Zuckermann
Ronald N. Zuckermann
JKJanice M. Kerr
Janice M. Kerr
WMWalter H. Moos
Walter H. Moos

1 April 1995 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
EMEric J. Martin
Eric J. Martin
JBJeffrey M. Blaney
Jeffrey M. Blaney
MSMichael A. Siani
Michael A. Siani
DSDavid C. Spellmeyer
David C. Spellmeyer
AWAlex K. Wong
Alex K. Wong
WMWalter H. Moos
Walter H. Moos

5 April 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
PMPeter B. Madrid
Peter B. Madrid
SCSidharth Chopra
Sidharth Chopra
IMIan D. Manger
Ian D. Manger
LGLynne Gilfillan
Lynne Gilfillan
TKTiffany R. Keepers
Tiffany R. Keepers
MTMary J. Tanga
Mary J. Tanga
The rapid development of effective medical countermeasures against potential biological threat agents is vital. Repurposing existing drugs that may have unanticipated activities as potential countermeasures is one way to meet this important goal, since currently approved drugs already have well-established safety and pharmacokinetic profiles in patients, as well as manufacturing and distribution networks. Therefore, approved drugs could rapidly be made available for a new indication in an emergency. A large systematic effort to determine whether existing drugs can be used against high containment bacterial and viral pathogens is described. We assembled and screened 1012 FDA-approved drugs for off-label broad-spectrum efficacy against Bacillus anthracis; Francisella tularensis; Coxiella burnetii; and Ebola, Marburg, and Lassa fever viruses using in vitro cell culture assays. We found a variety of hits against two or more of these biological threat pathogens, which were validated in secondary assays. As expected, antibiotic compounds were highly active against bacterial agents, but we did not identify any non-antibiotic compounds with broad-spectrum antibacterial activity. Lomefloxacin and erythromycin were found to be the most potent compounds in vivo protecting mice against Bacillus anthracis challenge. While multiple virus-specific inhibitors were identified, the most noteworthy antiviral compound identified was chloroquine, which disrupted entry and replication of two or more viruses in vitro and protected mice against Ebola virus challenge in vivo. The feasibility of repurposing existing drugs to face novel threats is demonstrated and this represents the first effort to apply this approach to high containment bacteria and viruses.

1 September 1984 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
JBJames A. Bristol
James A. Bristol
ISIla Sircar
Ila Sircar
WMWalter H. Moos
Walter H. Moos
DEDale B. Evans
Dale B. Evans
RWRonald E. Weishaar
Ronald E. Weishaar